RxDoctor Payments DataLook up a doctor →

M Chadi Alraies, MD

Interventional Cardiology · Detroit, MINPI 1689828238

Payments from drug & device makers

$245,411in general payments, 2019–2025

Across 438 payments — averaging $560.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$48K
  • Penumbra, Inc.$38K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$35K
  • Abiomed$21K
  • Shockwave Medical, Inc$18K
  • Novartis$18K
  • plus $68K from 42 others

What the payments were for

  • Consulting fees$104,28348%
  • Speaking & faculty fees$83,28239%
  • Travel & lodging$14,8437%
  • Food & beverage$13,5286%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245,411 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$305,983
Medicare patients
623
Services billed
3,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan145$164,585
EliquisApixaban124$117,609
JardianceEmpagliflozin99$110,683
XareltoRivaroxaban44$31,401
Repatha SureclickEvolocumab34$22,323
FarxigaDapagliflozin Propanediol15$20,634
BrilintaTicagrelor23$15,517
SymbicortBudesonide/Formoterol Fumarate14$3,644
Atorvastatin Calcium252$2,526
ClopidogrelClopidogrel Bisulfate176$2,294
Metoprolol Succinate159$2,011
Albuterol Sulfate HfaAlbuterol Sulfate74$1,781
Carvedilol179$1,302
Nifedipine ErNifedipine61$1,241
Pantoprazole Sodium75$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$17,790$164,585145 claims
PfizerEliquis$42$117,609124 claims
Boehringer IngelheimJardiance$6,703$110,68399 claims
AstraZenecaFarxiga, Brilinta, Symbicort$87$39,79552 claims
Johnson & JohnsonXarelto$131$31,40144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →